OVERVIEW OF ACTIVITY

Approximately 220,000 new cases of prostate cancer are diagnosed yearly in the US, accounting for approximately one third of new cancer cases in men. Published results from clinical trials lead to the emergence of new surgical and radiation therapy techniques and therapeutic agents, along with changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing urologist, radiation oncologist and medical oncologist must be well informed of these advances. To bridge the gap between research and practice, this issue of Prostate Cancer Update features one-on-one discussions with radiation oncologist Dr Anthony Zietman and medical oncologist Dr Nancy A Dawson. By providing information on the latest research developments and expert perspectives, this CME activity assists clinicians with the formulation of up-to-date clinical management strategies.

LEARNING OBJECTIVES

• Evaluate the clinical implications of emerging clinical trial data in prostate cancer screening, surveillance, prevention and treatment, and incorporate these data into management strategies in the settings of localized and advanced disease.
• Counsel appropriately selected patients with prostate cancer about the availability of ongoing clinical trials.
• Inform patients with prostate cancer about the specific risks and benefits of local therapies.
• Assess existing data and emerging research on the choice and timing of endocrine therapy, and apply this evidence to patient care decisions in the adjuvant and metastatic settings.
• Communicate the benefits and risks of employing taxane-based chemotherapy regimens for patients with biochemically recurrent or symptomatic metastatic prostate cancer.
• Appraise emerging data on biologic therapies, and consider the future clinical applicability for the treatment of patients with advanced prostate cancer.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains both audio and print components. To receive credit, the participant should listen to the CDs, review the Internet content and complete the Post-test and Educational Assessment located at www.ProstateCancerUpdate.com/CME. www.ProstateCancerUpdate.com contains edited comments, clinical trial schemas, graphics and references that supplement the audio program, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

This program is supported by educational grants from AstraZeneca Pharmaceuticals LP and Sanofi-Aventis.